Solazyme’s New Strain To Treat Diabetes
Solazyme which was originally founded to make low-carbon algal biofuels, has now acquired patent for using the strain of microalgae called Chlorella protothecoides in the treatment of glucose intolerance and diabetes. A 2008 study had already disclosed the benefit of C. protothecoides by resulting in considerable decrease in blood sugar levels after its consumption by the patients.
-Know more
Another study was conducted to address the physiological effects of Chlorella intake on subjects with high-risk factors for lifestyle-related diseases and healthy individuals. Gene profiling of the subjects showed variations before and after intake of Chlorella. This revealed that such gene profiles is thought to be directly related to uptake of glucose, indicating that the insulin signaling pathways could be a reason for hypoglycemic effects of chlorella.
Solazyme has found in animal testing that the algae decreased blood sugar levels without relying on insulin, as stated by Katie Ringer, the spokesperson of Solazyme. The patent also claims for the elimination of traditional treatments for diabetes and other illnesses by the consumption of algae.
The company also uses the algae strain to boost the relative abundance of beneficial stomach bacteria and has developed new strains of algae, which could be used as healthy substitutes for fat-and-cholesterol-laden butter, eggs, and other foods.
View the complete list of products from Algae
Click here
